OPRX - OptimizeRx trades high on positive Q4 guidance

OptimizeRx (OPRX) traded 5.5% higher premarket as it expects Q4 record revenue of ~$16M (+117% Y/Y) and positive GAAP net income.Revenue driven mainly by strong organic growth in messaging and patient engagement solutions.For FY20, the company estimates record revenue of ~$43M (+75% Y/Y).In 2020, OptimizeRx maintained a high client renewal rate while adding 60 new brands; CEO Steve Silvestro stated, "A high contract renewal rate and the increasing demand for effective digital provider and patient engagement solutions have fueled our growth. We began the new year with a sales pipeline of ~$170M, and it is showing a continued shift toward enterprise-level engagements that generate recurring revenue streams. Altogether, we expect another very strong year of growth ahead."SA Contributor Steve Auger assigned a Bullish rating in his recent article, "OptimizeRx: You Made Me A Believer"Earnings scheduled for Feb.25 release.

For further details see:

OptimizeRx trades high on positive Q4 guidance